admin@ataxiatelangiectasia.es
Start
Co to jest A-T?
Szukaj
News
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial
Odsłon: 161
EryDex
Quince Therapeutics
ChromaDex wins orphan designation for rare ataxia drug
Odsłon: 260
EryDex
Nicotinamide Riboside
ChromaDex
FDA
Nanopore Long-Read Sequencing Facilitates Diagnosis of Atypical Ataxia-Telangiectasia
Odsłon: 133
Korea
late onset variant
Nanopore
Neurology Genetics
IBEC and AEFAT join forces against ataxia telangiectasia
Odsłon: 80
Spain
AEFAT
IBEC
Organoids to study ataxia telangiectasia
Odsłon: 84
Spain
IBEC
organoids
Boston Children's Hospital lab trying to develop drug to treat boy's deadly rare disease
Odsłon: 121
ASO
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
Odsłon: 65
EryDex
FDA
Quince Therapeutics
Governor of Queensland Celebrates Ataxia Telangiectasia Clinical Trial
Odsłon: 73
Australia
Triheptanoin
Acasti reports results from ataxia telangiectasia therapy trial
Odsłon: 174
GTX-102
Acasti Pharma
A New Model for Neurodegenerative Disease
Odsłon: 73
pig model
Szukaj
Start
Co to jest A-T?
admin@ataxiatelangiectasia.es